引用本文:
本文已被:浏览 616次   下载 717
 
氯胺酮治疗难治性抑郁的研究现状
翟倩丰雷张国富刘敏王晶晶
()
fszhuche.com:
抑郁症是一种高患病率、高复发率、高自杀率的精神障碍,目前已经成为全世界所面临的 重大公共卫生问题。15%~20%的重度抑郁障碍会发展为难治性抑郁。然而目前传统的抗抑郁药物往 往需要2~3 周才能逐渐起效,延迟效应会导致患者自杀、自伤的风险升高。氯胺酮是一种临床常用的 全身麻醉药,自20 世纪90 年代初,发现其具有确切的抗抑郁效果,可以快速改善重度及难治性抑郁症 状。但是由于麻醉药品在临床上使用的限制以及可能带来物质滥用等其他问题,影响其临床推广。近 年来,氯胺酮治疗难治性抑郁的研究成为学术界热点。现就氯胺酮治疗难治性抑郁的机制、研究现状, 以及安全性方面进行综述。
关键词:  氯胺酮  难治性抑郁  综述
基金项目:国家科技重大专项(2018ZX09734-005)
Current status of ketamine therapy for treatment resistant depression
()
Abstract:
Depression is a mental disorder with a high prevalence rate, a high recurrence rate, and a high suicide rate. At present, it has become a major public health problem the world faced. 15 % -20 % of major depression can develop into treatment resistant depression. However, at present, traditional antidepressants often take 2 to 3 weeks to gradually take effect. Delayed effects can lead to increased risk of suicide and selfinjury in patients. Ketamine is a commonly used general anesthetic in the clinic. Since the early 1990s, it has been found that it has a definite antidepressant effect and can rapidly improve the symptoms of severe and treatment resistant depression. However, due to the restrictions on the clinical use of narcotic drugs and other problems such as substance abuse, the clinical promotion of narcotic drugs is affected. In recent years, ketamine in the treatment resistant depression has become a hot topic in academic circles. This article reviews the mechanism, research status and safety of ketamine in treatment resistant depression.

用微信扫一扫

用微信扫一扫